Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Catalyst Pharmaceuticals Total Assets 2010-2025 | CPRX

Catalyst Pharmaceuticals total assets from 2010 to 2025. Total assets can be defined as the sum of all assets on a company's balance sheet.
  
Catalyst Pharmaceuticals Annual Total Assets
(Millions of US $)
2024 $851
2023 $470
2022 $376
2021 $238
2020 $192
2019 $112
2018 $60
2017 $85
2016 $42
2015 $60
2014 $44
2013 $25
2012 $17
2011 $6
2010 $6
2009 $8
Catalyst Pharmaceuticals Quarterly Total Assets
(Millions of US $)
2025-03-31 $909
2024-12-31 $851
2024-09-30 $772
2024-06-30 $706
2024-03-31 $647
2023-12-31 $470
2023-09-30 $413
2023-06-30 $444
2023-03-31 $407
2022-12-31 $376
2022-09-30 $333
2022-06-30 $267
2022-03-31 $247
2021-12-31 $238
2021-09-30 $223
2021-06-30 $209
2021-03-31 $197
2020-12-31 $192
2020-09-30 $175
2020-06-30 $131
2020-03-31 $118
2019-12-31 $112
2019-09-30 $97
2019-06-30 $78
2019-03-31 $61
2018-12-31 $60
2018-09-30 $68
2018-06-30 $74
2018-03-31 $79
2017-12-31 $85
2017-09-30 $35
2017-06-30 $36
2017-03-31 $38
2016-12-31 $42
2016-09-30 $45
2016-06-30 $49
2016-03-31 $54
2015-12-31 $60
2015-09-30 $65
2015-06-30 $68
2015-03-31 $76
2014-12-31 $44
2014-09-30 $46
2014-06-30 $46
2014-03-31 $22
2013-12-31 $25
2013-09-30 $29
2013-06-30 $13
2013-03-31 $14
2012-12-31 $17
2012-09-30 $12
2012-06-30 $8
2012-03-31 $5
2011-12-31 $6
2011-09-30 $4
2011-06-30 $6
2011-03-31 $7
2010-12-31 $6
2010-09-30 $6
2010-06-30 $6
2010-03-31 $7
2009-12-31 $8
2009-09-30 $5
2009-06-30 $6
2009-03-31 $9
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $3.030B $0.492B
Catalyst Pharmaceuticals, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders, like Lambert-Eaton Myasthenic Syndrome (LEMS), epilepsy and Tourette syndrome. Catalyst in-licensed rights to Firdapse (for treating LEMS) from BioMarin Pharmaceutical Inc. for its development and commercialization in the U.S. Firdapse is currently approved in the European Union and in the U.S. for treating of LEMS in adults. The company also plans to file a supplemental new drug application for Firdapse to treat pediatric patients with LEMS.?The company is also strengthening the commercial portfolio of Firdapse. It has already received multiple patents that cover the treatment of all amifampridine metabolizer types within the LEMS patient population.?Apart from Firdapse, the company is working on a generic version of Lundbeck's Sabril, CPP-109, for the treatment of infantile spasms and complex partial seizures.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $87.311B 32.75
Zoetis (ZTS) United States $74.020B 27.62
Daiichi Sankyo, - (DSNKY) Japan $51.315B 26.11
Takeda Pharmaceutical (TAK) Japan $46.678B 9.28
Sandoz Group AG (SDZNY) Switzerland $21.655B 0.00
Summit Therapeutics (SMMT) United States $19.042B 0.00
Merck (MKKGY) Germany $17.125B 12.55
United Therapeutics (UTHR) United States $14.201B 12.56
Shionogi (SGIOY) Japan $14.121B 14.15
Neurocrine Biosciences (NBIX) United States $12.137B 41.57
IPSEN (IPSEY) France $9.821B 0.00
Orion OYJ (ORINY) Finland $9.323B 25.21
Corcept Therapeutics (CORT) United States $8.145B 66.22
Stevanato Group S.p.A (STVN) Italy $6.917B 42.30
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.153B 0.00
Madrigal Pharmaceuticals (MDGL) United States $6.030B 0.00
Grifols, S.A (GRFS) Spain $5.659B 0.00
Ionis Pharmaceuticals (IONS) United States $5.303B 0.00
Ono Pharmaceutical (OPHLF) Japan $4.875B 14.83
Soleno Therapeutics (SLNO) United States $3.843B 0.00
Hypermarcas (HYPMY) Brazil $2.873B 18.90
Crinetics Pharmaceuticals (CRNX) United States $2.762B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.285B 12.36
BioCryst Pharmaceuticals (BCRX) United States $2.258B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $1.910B 0.00
Recursion Pharmaceuticals (RXRX) United States $1.785B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $1.705B 0.00
Indivior (INDV) United States $1.630B 6.92
Evotec AG (EVO) Germany $1.518B 0.00
ARS Pharmaceuticals (SPRY) United States $1.436B 0.00
Guardian Pharmacy Services (GRDN) United States $1.401B 0.00
Dyne Therapeutics (DYN) United States $1.330B 0.00
Ocular Therapeutix (OCUL) United States $1.106B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.101B 22.03
Harrow (HROW) United States $0.966B 0.00
Ardelyx (ARDX) United States $0.950B 0.00
Collegium Pharmaceutical (COLL) United States $0.947B 5.11
Avadel Pharmaceuticals (AVDL) Ireland $0.876B 0.00
Enliven Therapeutics (ELVN) United States $0.785B 0.00
Cronos Group (CRON) Canada $0.771B 0.00
Akebia Therapeutics (AKBA) United States $0.767B 0.00
Xeris Biopharma Holdings (XERS) United States $0.755B 0.00
AleAnna (ANNA) United States $0.675B 0.00
Elite Pharmaceuticals (ELTP) United States $0.568B 0.00
USANA Health Sciences (USNA) United States $0.566B 12.30
KalVista Pharmaceuticals (KALV) United States $0.558B 0.00
Xencor (XNCR) United States $0.552B 0.00
Regulus Therapeutics (RGLS) United States $0.548B 0.00
Bioventus (BVS) United States $0.536B 13.60
Relay Therapeutics (RLAY) United States $0.489B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.464B 0.00
Zevra Therapeutics (ZVRA) United States $0.462B 0.00
Altimmune (ALT) United States $0.447B 0.00
Siga Technologies (SIGA) United States $0.434B 9.07
Oruka Therapeutics (ORKA) United States $0.428B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.421B 0.00
CytoDyn (CYDY) United States $0.406B 0.00
Tourmaline Bio (TRML) United States $0.398B 0.00
Verve Therapeutics (VERV) United States $0.382B 0.00
Organogenesis (ORGO) United States $0.377B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.351B 9.48
Savara (SVRA) United States $0.335B 0.00
Heron Therapeutics (HRTX) United States $0.288B 0.00
Nature's Sunshine Products (NATR) United States $0.272B 25.14
Tonix Pharmaceuticals Holding (TNXP) United States $0.271B 0.00
Aquestive Therapeutics (AQST) United States $0.253B 0.00
MediWound (MDWD) Israel $0.230B 0.00
ProKidney (PROK) United States $0.214B 0.00
Journey Medical (DERM) United States $0.181B 0.00
Wellgistics Health (WGRX) United States $0.180B 0.00
Nanobiotix S.A (NBTX) France $0.180B 0.00
Esperion Therapeutics (ESPR) United States $0.163B 0.00
OmniAb (OABI) United States $0.162B 0.00
Avita Medical (RCEL) United States $0.160B 0.00
Profound Medical (PROF) Canada $0.159B 0.00
4D Molecular Therapeutics (FDMT) United States $0.158B 0.00
Aclaris Therapeutics (ACRS) United States $0.138B 0.00
Liminatus Pharma (LIMN) $0.132B 0.00
Aldeyra Therapeutics (ALDX) United States $0.132B 0.00
Inhibikase Therapeutics (IKT) United States $0.132B 0.00
Nektar Therapeutics (NKTR) United States $0.126B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.124B 0.00
Protara Therapeutics (TARA) United States $0.122B 0.00
Innate Pharma SA (IPHYF) France $0.122B 0.00
Lyell Immunopharma (LYEL) United States $0.121B 0.00
Korro Bio (KRRO) United States $0.120B 0.00
Larimar Therapeutics (LRMR) United States $0.117B 0.00
Achieve Life Sciences (ACHV) Canada $0.110B 0.00
VAXART, INC (VXRT) United States $0.105B 0.00
Cassava Sciences (SAVA) United States $0.103B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.101B 0.00
OptiNose (OPTN) United States $0.097B 0.00
Cardiol Therapeutics (CRDL) Canada $0.096B 0.00
Fractyl Health (GUTS) United States $0.096B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.090B 0.00
Lexeo Therapeutics (LXEO) United States $0.090B 0.00
Inotiv (NOTV) United States $0.088B 0.00
Arch Biopartners (ACHFF) Canada $0.084B 0.00
Galectin Therapeutics (GALT) United States $0.083B 0.00
Champions Oncology (CSBR) United States $0.083B 13.61
Cumberland Pharmaceuticals (CPIX) United States $0.080B 59.33
Pyxis Oncology (PYXS) United States $0.077B 0.00
ESSA Pharma (EPIX) Canada $0.071B 0.00
Unicycive Therapeutics (UNCY) United States $0.071B 0.00
Dominari Holdings (DOMH) United States $0.069B 0.00
Vivani Medical (VANI) United States $0.068B 0.00
Nutriband (NTRB) United States $0.067B 0.00
Surrozen (SRZN) United States $0.066B 0.00
Assertio Holdings (ASRT) United States $0.065B 0.00
Telomir Pharmaceuticals (TELO) United States $0.063B 0.00
Metagenomi (MGX) United States $0.062B 0.00
Context Therapeutics (CNTX) United States $0.061B 0.00
Allergy Therapeutics (AGYTF) United Kingdom $0.059B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.053B 0.00
Gain Therapeutics (GANX) United States $0.052B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.051B 0.00
Century Therapeutics (IPSC) United States $0.048B 0.00
PMV Pharmaceuticals (PMVP) United States $0.047B 0.00
Mural Oncology (MURA) Ireland $0.045B 0.00
Prelude Therapeutics (PRLD) United States $0.045B 0.00
NRx Pharmaceuticals (NRXP) United States $0.045B 0.00
Karyopharm Therapeutics (KPTI) United States $0.039B 0.00
Avalo Therapeutics (AVTX) United States $0.039B 0.00
Iterum Therapeutics (ITRM) Ireland $0.038B 0.00
ElectroCore (ECOR) United States $0.036B 0.00
Acrivon Therapeutics (ACRV) United States $0.034B 0.00
FibroGen (FGEN) United States $0.032B 0.00
Rafael Holdings (RFL) United States $0.032B 0.00
SCYNEXIS (SCYX) United States $0.028B 0.00
PolyPid (PYPD) Israel $0.026B 0.00
China SXT Pharmaceuticals (SXTC) China $0.024B 0.00
Enlivex Therapeutics (ENLV) Israel $0.024B 0.00
CASI Pharmaceuticals (CASI) China $0.023B 0.00
Tempest Therapeutics (TPST) United States $0.023B 0.00
Relmada Therapeutics (RLMD) United States $0.022B 0.00
Jupiter Neurosciences (JUNS) United States $0.021B 0.00
Natural Alternatives (NAII) United States $0.020B 0.00
BioVie (BIVI) United States $0.019B 0.00
Lipocine (LPCN) United States $0.019B 0.00
Mannatech (MTEX) United States $0.018B 0.00
TherapeuticsMD (TXMD) United States $0.017B 0.00
DURECT (DRRX) United States $0.016B 0.00
SHINECO (SISI) China $0.015B 0.00
VYNE Therapeutics (VYNE) United States $0.015B 0.00
ProPhase Labs (PRPH) United States $0.015B 0.00
Ernexa Therapeutics (ERNA) United States $0.015B 0.00
GlycoMimetics (GLYC) United States $0.015B 0.00
MEI Pharma (MEIP) United States $0.014B 0.00
Cosmos Health (COSM) United States $0.013B 0.00
Vivos Therapeutics (VVOS) United States $0.013B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.013B 0.00
Ainos (AIMD) United States $0.013B 0.00
BioLineRx (BLRX) Israel $0.012B 0.00
Scienture Holdings (SCNX) United States $0.012B 0.00
Minerva Neurosciences (NERV) United States $0.010B 1.82
Talphera (TLPH) United States $0.010B 0.00
Mangoceuticals (MGRX) United States $0.010B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.009B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
Phio Pharmaceuticals (PHIO) United States $0.008B 0.00
Biomerica (BMRA) United States $0.008B 0.00
Incannex Healthcare (IXHL) Australia $0.008B 0.00
Carisma Therapeutics (CARM) United States $0.008B 0.00
Traws Pharma (TRAW) United States $0.008B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.007B 0.00
Citius Pharmaceuticals (CTXR) United States $0.007B 0.00
Nuvilex (PMCB) United States $0.007B 0.00
Klotho Neurosciences (KLTO) United States $0.007B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.006B 0.00
Lyra Therapeutics (LYRA) United States $0.006B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.006B 0.00
TransCode Therapeutics (RNAZ) United States $0.006B 0.00
Indaptus Therapeutics (INDP) United States $0.005B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.005B 0.00
Plus Therapeutics (PSTV) United States $0.005B 0.00
Aptorum Group (APM) United Kingdom $0.005B 0.00
Xenetic Biosciences (XBIO) United States $0.004B 0.00
Alaunos Therapeutics (TCRT) United States $0.004B 0.00
Clearmind Medicine (CMND) Canada $0.004B 0.00
CERo Therapeutics Holdings (CERO) United States $0.004B 0.00
PainReform (PRFX) Israel $0.004B 0.00
Aditxt (ADTX) United States $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.003B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.003B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
SciSparc (SPRC) Israel $0.003B 0.00
Redhill Biopharma (RDHL) Israel $0.003B 0.00
Heatwurx (PCSA) United States $0.003B 0.00
Jaguar Animal Health (JAGX) United States $0.003B 0.00
Conduit Pharmaceuticals (CDT) United States $0.003B 0.00
Qualigen Therapeutics (QLGN) United States $0.003B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
TNF Pharmaceuticals (TNFA) United States $0.002B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
Universe Pharmaceuticals INC (UPC) China $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Silence Therapeutics (SLN) United Kingdom $0.000B 0.00